RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

Pharmaceutical Industry

A collection of news and information related to Pharmaceutical Industry published by this site and its partners.

Top Pharmaceutical Industry Articles

Displaying items 34-44
  • AbbVie sued by FTC for paying to delay generic drug

    AbbVie sued by FTC for paying to delay generic drug
    The Federal Trade Commission has filed suit against North Chicago-based AbbVie and a partner, alleging the companies illegally blocked consumer access to generic versions of the testosterone replacement drug AndroGel in order to reap hundreds of...
  • Protalix shares wipe out gains as CEO clarifies Ebola possibilities

    JERUSALEM (Reuters) - Shares of Israeli biotech firm Protalix reversed gains on Sunday after the company's chief executive threw cold water on a news report that its technology could be used to develop a version of the Ebola experimental drug ZMapp....
  • Chicago misses out in AbbVie-Calico pharma deal

     Chicago misses out in AbbVie-Calico pharma deal
    A few days ago, Calico, a Google-backed biotech company, announced that it would build a California-based research and development facility to invent new drugs to combat diseases afflicting the elderly. Half of the initial $500 million investment...
  • AbbVie partners with Google to develop new drugs for aging

    AbbVie partners with Google to develop new drugs for aging
    A startup backed by Google, the Silicon Valley powerhouse whose innovations range from its eponymous search engine to self-driving cars, is teaming up with a North Chicago drug company to develop treatments for diseases tied to aging. Drugmaker AbbVie...
  • Facing shareholder demands, Allergan calls special meeting for December 18

    (Reuters) - Allergan Inc said on Tuesday that it has scheduled a special shareholders meeting for Dec. 18, when activist investor Bill Ackman, who supports a hostile bid for the company by Valeant Pharmaceuticals Inc, will attempt to oust most of its...
  • Allergan sets shareholder meeting on hostile takeover attempt

    Allergan sets shareholder meeting on hostile takeover attempt
    Allergan Inc. scheduled a Dec. 18 special meeting of its shareholders that could ultimately resolve a hostile takeover attempt by a Canadian rival. Valeant Pharmaceuticals International Inc., which is based near Montreal, has been fighting since April...
  • Pfizer to test Xalkori lung cancer drug with Merck immunotherapy

    (Reuters) - Pfizer Inc said Tuesday it will test its Xalkori lung cancer drug with Merck & Co's experimental immunotherapy pembrolizumab, in hopes the combination will improve the outcomes for patients taking the approved Pfizer therapy. The largest U.S....
  • No biotech copycat drug lift off before 2017: Novartis CEO

    BASEL Switzerland (Reuters) - Swiss drugmaker Novartis AG does not expect copycat versions of biotech drugs to play an important role in the healthcare system for another three to five years, its chief executive said on Monday. Novartis' generics unit...
  • Roche to buy U.S. biotech firm InterMune for $8.3 billion

    Roche to buy U.S. biotech firm InterMune for $8.3 billion
    Roche Holding AG has agreed to buy U.S. biotech company InterMune Inc. for $8.3 billion in cash, helping the world's leading maker of cancer drugs expand into the treatment of rare or incurable diseases. Roche's efforts to produce successful non-...
  • Baxter reports success in late-stage trial on extended release hemophilia drug

    Baxter reports success in late-stage trial on extended release hemophilia drug
    Baxter International Inc. said Thursday a key hemophilia drug under development met its primary goal in a late-stage clinical study. The drug, known as BAX 855, is essentially a stronger, extended-release version of its flagship hemophilia drug Advate,...
  • U.S. clears AstraZeneca over heart drug trial

    LONDON (Reuters) - The U.S. government has cleared AstraZeneca Plc over a major clinical trial used to win marketing approval for its important new heart drug Brilinta, following an investigation which had cast a shadow over its prospects. The drugmaker...